
Supplementary information

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

In the format provided by the authors and unedited




Fig. S1. Gating strategy of the S-Flow assay

293T cells were transiently transfected with plasmids expressing the D614G, B.1.1.7 and B.1.351 Spikes. After 24h, cells were stained with anti SARS-CoV-2 antibodies mAb10 (a pan-coronavirus antibody), mAb48, mAb102 or soluble ACE2 (ACE2- biotin at 20 μ g/ml revealed with fluorescent Streptavidin) and analyzed by flow-cytometry. A. One representative example of the gating strategy is shown. Gates are set on cells transfected with an empty plasmid. b. An example of the signal obtained by a reactive serum on spike expressing cells is shown.




Fig. S2. Absence of detection of a neutralizing activity in 10 pre-pandemic nasal swabs. Neutralization curves with nasal swabs from individuals collected in 2018 for Flu-diagnostic purposes. The antiviral activity was measured at the indicated dilutions against D614G, B.1.1.7 and B.1.351 variants. Data are mean \pm SEM of 10 different samples. One experiment representative of two is shown.

Table S1a: Orléans Cohort

		total n = 28
sex	female	17
	male	11
Age		56.9 (46-69)
Severity	Critical	3
	Severe	13
	Mild-Moderate	11
	Asymptomatic	1
HIV		2
PCR		26
Anti-S (S-Flow)		28
1st sampling (days)		89 (71-105)
2nd sampling (days)		177 (164-197)

Table S1b: Strasbourg Cohort

		total n = 30
sex	female	27
	male	3
Age		44.8 (25-54)
Severity	Critical	0
	Severe	0
	Mild-Moderate	30
	Asymptomatic	0
HIV		0
PCR		30
Anti-S (S-Flow)		30
Sampling (days)		233 (206-258)

Table S2: Orléans Vaccinees

		total n = 19
sex	female	6
	male	13
Age		55 (46-63)
BMI		24.2 (21.9-24.7)
Immune deficiency		0
Previous COVID-19		3
Vaccine	Pfizer-BioNTech	19
	Moderna	0
	AstraZeneca	0
1st shot		4-13 january 2021
Sampling	Week 2	17
	Week 3	18
	Week 4	11
	Week 5	16
	Week 6	15